Scientech Research LLC Purchases Shares of 20,029 Twist Bioscience Corporation $TWST

Key Points

• Scientech Research LLC acquired a new stake in Twist Bioscience Corporation, purchasing 20,029 shares valued at approximately $786,000 in the first quarter.
• Twist Bioscience reported a loss of $0.47 per share for the last quarter, which was better than the analyst consensus estimate of a loss of $0.54.
• Research analysts have a consensus price target of $49.40 for Twist Bioscience, with nine analysts rating it as a "Buy."

Scientech Research LLC bought a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,029 shares of the company's stock, valued at approximately $786,000.

Several other large investors have also made changes to their positions in TWST. Farther Finance Advisors LLC raised its position in Twist Bioscience by 18.5% in the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock valued at $251,000 after purchasing an additional 1,006 shares during the period. GAMMA Investing LLC raised its position in Twist Bioscience by 6,499.1% in the first quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock valued at $1,153,000 after purchasing an additional 28,921 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new position in Twist Bioscience in the first quarter valued at about $396,000. SG Americas Securities LLC purchased a new position in Twist Bioscience in the first quarter valued at about $893,000. Finally, Hsbc Holdings PLC purchased a new position in Twist Bioscience in the first quarter valued at about $228,000.

Analyst Ratings Changes

TWST has been the topic of a number of analyst reports. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Stock Performance

NASDAQ:TWST traded up $1.45 during midday trading on Thursday, reaching $25.61. 1,965,255 shares of the company traded hands, compared to its average volume of 1,369,911. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a fifty day moving average price of $30.77 and a 200 day moving average price of $34.37.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $25.76, for a total value of $58,346.40. Following the completion of the sale, the chief executive officer owned 634,740 shares of the company's stock, valued at $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,911 shares of company stock valued at $288,159. Insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.